Floatz logo

mln9708

Multiple Myeloma

Navy General Hospital, BeijingPhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
70/ 100
Competitive Position
59/ 100

Competitive context

343 Active assets in the Multiple Myeloma cohort.

Asset / SponsorPhaseRating
Thalidomide
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BB
Inno-206
GlaxoSmithKline
Phase 4BB
PREDNISONE TABLETS
GlaxoSmithKline
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Janssen Research & Development, LLC
Phase 4BB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 4BB

View all 50 →

Same molecule, other indications

mln9708 is also rated in:

AmyloidosisDormant
BB
Indicative ·
64 / 100
View asset →
Higher-risk Myelodysplastic SyndromeDormant
B
Indicative ·
61 / 100
View asset →
Hematopoietic Cell Transplantation RecipientDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →